Interactions between the histone deacetylase inhibitor SAHA and the pharmacologic MEK1/2 inhibitor PD184352 were examined in Bcr/Abl þ human leukemia cells. Coadministration of minimally toxic concentrations of SAHA (or sodium butyrate) and PD184352 (or U0126) resulted in a synergistic increase in mitochondrial damage, caspase activation, and apoptosis in K562 and LAMA 84 cells. Similar interactions were observed in CD34 þ cells from two patients with CML and in imatinib mesylate-resistant K562 cells but not in normal human CD34 þ bone marrow cells. These events were associated with a marked increase in ROS generation, inactivation of ERK and Akt, downregulation of p21 CIP1 , Bcr/Abl, and cyclin D 1 , and activation of JNK. Of these events, ROS generation, ERK inactivation, and cytochrome c/AIF release were largely caspase-independent, whereas the other phenomena displayed varying degrees of caspase-dependence. Using pharmacologic and genetic approaches, generation of ROS, p21 CIP1 downregulation, and inactivation of Akt and MEK were found to play significant functional roles in SAHA/PD184352-mediated lethality, whereas JNK activation and Raf-1 downregulation were determined to represent secondary events. These findings indicate that interruption of the MEK/ERK pathway substantially lowers the threshold for HDAC inhibitor-mediated oxidative injury, mitochondrial dysfunction, and apoptosis, suggesting that this approach warrants further examination in Bcr/Abl þ -related malignancies.
Introduction
Chronic myelogenous leukemia (CML) is a hematologic malignancy characterized by the Philadelphia chromosome, formed by the reciprocal translocation of the long arms of chromosome 9 and chromosome 22. 1 This mutant gene encodes the constitutively active Bcr/Abl kinase, which signals downstream to a variety of cytoprotective pathways including extracellular signal-regulated kinase (ERK), Akt, NF-kB, Jak/ STAT, and Bcl-x L , among others. [2] [3] [4] Collectively, activation of these pathways confers a survival advantage on Bcr/Abl þ cells, and is responsible for leukemic transformation. 5 In addition to promoting leukemic cell survival, the Bcr/Abl kinase renders cells resistant to a wide range of conventional cytotoxic drugs active in leukemia. 6 The treatment of CML has been revolutionized by the introduction of small molecule Bcr/Abl kinase inhibitors, the prototype of which is STI571 or imatinib mesylate. 7 While imatinib mesylate is highly active in patients with untreated CML, it is less so in patients with accelerated or blast phase disease. 8 Furthermore, the pre-existence or emergence of imatinib mesylate resistance through either gene amplification or mutation represents a continuing challenge to curative approaches to this disorder. 9 Recently, novel Bcr/Abl kinase inhibitors have been developed (eg BMS-354825), which are considerably more potent on a molar basis than imatinib mesylate, and which retain activity against some Bcr/Abl mutations that confer imatinib resistance. 10 Nevertheless, cells bearing certain mutations (eg T315I) remain highly resistant to these agents. 10 Consequently, the development of newer strategies in CML continue to be a high priority.
Histone deacetylase inhibitors (HDACIs) represent a class of agents that block the actions of histone deacetylases, enzymes which, in conjunction with histone acetylases (HATs) govern the acetylation status of histones. 11 HDACIs promote histone acetylation, which favors a more open chromatin structure generally, although not universally, associated with enhanced gene transcription. 12 When administered at relatively low concentrations, HDACIs such as the short-chain fatty acid sodium butyrate or the hydroxamic acid SAHA (suberanoylanilide hydroxamic acid) trigger leukemic cell maturation. 13, 14 However, when administered at higher concentrations, apoptosis ensues. 15 The mechanism underlying HDACI lethality in human leukemia cells is not known with certainty, but may be related to one or more of the pleiotropic actions of these agents, including generation of reactive oxygen species (ROS) and Bid cleavage, 16 interference with Hsp90 function, 17, 18 induction of death receptors, 19 and generation of ceramide, 20 among others. In this context, we have recently reported that induction of apoptosis in Bcr/Abl þ leukemia cells by SAHA was associated with ROS generation and reciprocal effects on the stress-related JNK (c-Jun N-terminal kinase) and cytoprotective ERK pathways. 21 The Raf/MEK (mitogen-actived protein kinase kinase)/ERK pathway comprises, along with the JNK and p38 MAP kinase modules, members of the MAP kinase cascades. 22 These kinase modules are involved in the control of cellular proliferation, survival, differentiation, and stress responses, among other processes. Although exceptions exist, ERK activation is generally associated with enhanced cell survival whereas JNK and p38 MAPK are associated with cell death. 23 ERK activation has also been shown to play an important role in protecting cells from the otherwise lethal effects of oxidative stress. 24 For these and other reasons, small molecule inhibitors of the cytoprotective MEK/ERK pathway have become the focus of considerable interest as antineoplastic agents, 25 and the MEK inhibitor PD184352 (CI-1040) has recently entered the clinical arena. 26 Aside from antagonizing leukemic cell survival, interruption of ERK signaling (eg by MEK inhibitors) can also lower the threshold for apoptosis induced by other novel signaling/survival inhibitors (eg UCN-01, farnesyltransferase inhibitors). 27, 28 In view of the established role of ERK activation in protecting cells from oxidative injury, 24 as well as evidence that HDACIs exert their lethal effects, at least in part, through induction of ROS, 16 the possibility arose that exposure of human leukemia cells to MEK inhibitors would lower the threshold for HDACI-mediated apoptosis. The purpose of the present studies was to determine whether in fact such an interaction would occur in Bcr/Abl þ leukemia cells known to be resistant to more conventional cytotoxic agents 6 as well as imatinib mesylate, and if so, to examine possible mechanisms underlying this phenomenon. Our results indicate that MEK inhibitors interact in a highly synergistic manner with SAHA in Bcr/Abl þ leukemia cells to induce mitochondrial injury and apoptosis, but are relatively nontoxic to normal CD34 þ bone marrow cells. Furthermore, these events result at least in part from ROS generation, and involve inhibition of p21 CIP1 induction as well as MEK/ERK and Akt inactivation. Together, these findings raise the possibility that combined treatment with HDAC and MEK inhibitors warrants further examination as an antileukemic strategy in certain Bcr/Abl þ hematologic malignancies.
Materials and methods

Cells
LAMA 84 cells were purchased from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). K562 cells were obtained as described previously. 21 All were cultured in RPMI 1640 supplemented with sodium pyruvate, MEM essential vitamins, L-glutamate, penicillin, streptomycin, and 10% heat-inactivated FCS (Hyclone, Logan, UT, USA). CD34 þ cells were obtained with informed consent from the bone marrow of two patients with chronic phase CML undergoing a routine diagnostic bone marrow aspiration, or from a patient undergoing a routine diagnostic aspiration for a nonmyeloid hematologic disorder (thrombocytopenia). These studies have been sanctioned by the Institutional Review Board of Virginia Commonwealth University/Medical College of Viriginia. Blood was collected into heparinzed syringes, diluted 1:3 with RMPI 1640 medium, and transferred as an overlayer to centrifuge tubes containing 10 ml of Ficoll-Hypaque (sp. grav. 1.077-1.081; Sigma, St Louis, MO, USA). After centrifugation at room temperature for 30 min, the interface layer, containing mononuclear cells, was extracted with a sterile Pasteur pipette, suspended in RPMI medium, and washed three times. CD34 þ cells were then isolated using a Miltenyi microbead separation system (Miltenyi BioTech; Auburn, CA, USA) as per the manufacturer's instructions. The CD34 þ cells were then diluted into RPMI medium containing 10% fetal calf serum at a concentration of 2 Â 10 5 cells/ml, and exposed to drugs same as K562 cells.
Reagents
Sodium butyrate, U0126, SP600125 and SB203580 were supplied by Calbiochem, San Diego, CA, USA. BOC-fmk was purchased from Enzyme Products, Ltd, USA. Livermore, CA, USA. SAHA was purchased from Alexis Corp., San Diego, CA, USA. All drugs were formulated in sterile DMSO before use. PD184352 was obtained as previously described. 27 Annexin V/ PI was supplied by BD PharMingen, San Diego, CA, USA and formulated as per the manufacturer's instructions. 7-AminoactinomycinD (7-AAD) was purchased from Sigma-Aldrich. VIAcount buffers used in GUAVA analysis and cell viability assays (Guava Technologies, Hayward, CA, USA) was procured from the manufacturer. All transient transfection reagents were procured from Amaxa, Germany through their US operation at Rockville, MD, USA. Trypan Blue working solution was purchased from Invitrogen.
Experimental format
Logarithmically growing cells were placed in sterile plastic T-flasks (Corning, Corning, NY, USA) to which were added the designated drugs. The flasks were then placed in a 5% CO 2 , 371C incubator for various intervals. At the end of the incubation period, cells were transferred to sterile centrifuge tubes, pelleted by centrifugation at 400 g for 10 min at room temperature, and prepared for analysis as described below.
Assessment of apoptosis
Apoptotic cells are evaluated by Annexin V/PI staining and in some cases verified by Wright-Giemsa Staining as described previously. 21 In brief, morphologically apoptotic cells were identified by classical features, that is, nuclear condensation, cell shrinkage, formation of apoptotic bodies in slides. Alternatively, the annexin V/PI assay was carried out as per the manufacturer's instructions (BD PharMingen, San Diego, CA, USA) using a Becton Dickinson FACScan flow cytometer. In general, the results of morphologic assessment and annexin V/PI staining yielded highly concordant results.
Assessment of cell viability
Drug effects on cell viability were monitored by flow cytometry using 7AAD as the staining dye as previously described. 29 Briefly, cells were stained with 25 mM 7AAD solution at room temperature in regular culture media and analyzed in the FL2 channel using the Becton Dickinson flow cytometer. Cells were also analyzed for viability using the VIACOUNT reagent in conjunction with a GUAVA PCA instrument using CytoSoft software as per the manufacturers instruction. Results were also verified by Trypan blue staining and enumeration of Trypan blue excluding cells using a hemocytometer. Results for each method were found to be in good agreement.
Preparation of S-100 fractions and assessment of cytochrome c release K562 and LAMA 84 cells were harvested after drug treatment and cytosolic S-100 fractions were prepared as described in detail previously. 27 Western blot analysis assessing cytochrome c release was performed as described below.
Immunoblot analysis
Immunoblotting was performed as described previously. 27 The source of primary antibodies were as follows: AIF, cytochrome c, p-JNK, JNK1, JNK2, p-ERK, ERK, Raf-1, HA-MEK, Akt, p-Akt, Mcl-1, Bax, Bcl-x L were from Santa Cruz Biotechnology, Santa Cruz, CA, USA; Bcr/Abl, Cleaved caspase-3, Cleaved caspase-9, p-p38, Bid were from Cell Signaling Technology, Beverly, MA, USA; p21, MEK1 were from Transduction Laboratories, Lexington, KY; PARP (C-2-10) was from, BioMol Research Laboratories, Plymouth, MA, USA; Smac was from Upstate Biotechnology, Lake Placid, NY; Caspase-8 was from Alexis, San Diego, CA, USA; Bak, Tubulin was from Oncogene, San Diego, CA, USA. XIAP was from R&D systems, Minneapolis, MN, USA. cyclin D1 was from BD Pharmingen, San Diego, CA, USA.
Measurement of ROS production
Cells are treated with 20 mM 2 0 ,7 0 -dicholorodihydrofluorescein diacetate for 30 min at 371C and fluorescence was measured by flow cytometry on a fluorescence-activated cell sorting scan and analyzed with CELL Quest software.
Plasmids and siRNA
Plasmids encoding enhanced green fluorescence protein under the transcriptional control of the human cytomegalovirus (CMV) immediate-early promoter (pEGFP-C2) was obtained from Clontech Laboratories (Palo Alto, CA, USA), and the human p21 CIP1 cDNA was a kind gift from Dr Stephen Elledge (Harvard University Medical School, Boston). The entire p21
CIP1 cDNA was inserted in-frame into the (C-terminal) multiple cloning site of pEGFP-C2. The full-length p21 CIP1 cDNA in the fusion construct was sequenced and the reading frame was confirmed. Akt1 cDNA in pUSEamp was purchased from Upstate biotechnology, Lake Placid, NY, USA amplified, made endotoxin free, and used in transient transfection. JNK1 siRNA was obtained from Orbigen, San Diego, CA, USA. Constitutively active MEK1-CA and Raf-1-CA cDNAs were also obtained from Uptate biotechnology, Lake Placid, NY, USA.
Transient transfections
Transient transfection of K562 cells are carried out using an Amaxa Nucleofector apparatus (Cologne, Germany) as per the manufacturer's protocol. Optimized protocols for each cell line were employed using transfection kit V. Briefly, cells were cultured for 2 days prior to transfection but not allowed to grow beyond a concentration of 5 Â 10 5 cells/ml before transfection. One million cells were pelleted by centrifugation and resuspended in 100 ml of transfection reagent of kit V after which 2.5 mg of DNA was added. Resuspended cells in medium containing DNA was transferred to cuvettes and transfected using the Nuclofector using a cell-specific optimized protocol (T-16). Transfected cells were immediately transferred to regular medium (5 ml) and exposed to the indicated drugs after 24 h.
Statistical analysis
The significance of differences between experimental conditions was determined using the two-tailed Student's t-test. Characterization of synergistic and antagonistic interactions was performed using Median Dose Effect analysis in conjunction with a commercially available software program (CalcuSyn, Biosoft, Ferguson, MO, USA). 30 
Results
Interactions between PD184352 and SAHA in Bcr/Abl þ human leukemia cells (K562) were first examined. Whereas SAHA (2.0 mM; 48 h) by itself was minimally toxic, coadministration of 5 mM PD184352, which administered alone was nontoxic, resulted in a significant increase in cell death ( Figure 1a ). Higher, marginally toxic concentrations of PD184352 resulted in progressively greater potentiation of SAHA lethality. A SAHA dose-response study revealed that 10 mM PD184352 slightly increased the lethality of 1.0 mM SAHA, but very substantially increased cell death triggered by SAHA concentrations X1.5 mM (Figure 1b) . A time course study revealed that a relatively modest increase in apoptosis in PD184352/SAHA-treated cells was first noted 12-24 h after drug exposure, but became progressively more pronounced after 36-48 h (Figure 1c ). Finally, median dose effect analysis of apoptosis induced by PD184352 and SAHA, administered at a fixed ratio (5:1) yielded combination index (CI) values considerably less than 1.0, corresponding to a highly synergistic interaction (Figure 1d ). Lastly, combined treatment resulted in enhanced lethality, reflected by annexin V positivity, in CD34 þ cells obtained from the bone marrow of two separate patients with chronic phase CML (Figure 1e ). In contrast, normal bone marrow CD34 þ cells displayed essentially no increase in lethality following combined exposure to these agents.
To establish whether this phenomenon was restricted to K562 cells, parallel studies were carried out in another Bcr/Abl þ human leukemia cell line, LAMA 84. Although these cells were slightly more sensitive to SAHA administered alone than their K562 counterparts, subtoxic concentrations of PD184352 synergistically increased SAHA lethality in these cells as well Attempts were then made to extend these findings to (a) other HDAC inhibitors and (b) other MEK inhibitors. As shown by the data in Table 1 , synergistic potentiation of lethality in K562 and LAMA 84 cells was observed when PD184352 was combined with a minimally toxic concentration of the HDAC inhibitor sodium butyrate, and when SAHA was combined with a nontoxic concentration of the MEK inhibitor U0126.
Effects of combining SAHA with PD184352 in K562 cells was then examined in relation to mitochondrial injury, caspase activation, and expression of various antiapoptotic proteins. Whereas exposure to 2.0 mM SAHA or 10 mM PD184352 individually had very modest or no effects on release of cytochrome c, AIF (apoptosis-inducing factor), and Smac/ DIABLO into the cytosolic S-100 fraction, combined treatment resulted in a marked redistribution of these proapoptotic proteins into the cytosolic component ( Figure 3a) . Consistent with these findings, combined but not individual treatment resulted in a pronounced increase in cleavage of caspases-3, -9, and -8, and degradation of PARP and Bid (Figure 3b ). Lastly, neither combined nor individual exposure to these agents significantly modified expression of Bcl-x L , Bax, Mcl-1, Bak, or XIAP ( Figure 3c ). As previously reported, Bcl-2 levels were very low in these cells, 31 and did not change appreciably following individual or combined drug exposure (data not shown).
The effects of individual and combined exposure to PD184352 and SAHA on expression of various cell cycle and signal transduction pathways in K562 cells was then investigated. As observed previously, 32 exposure to SAHA robustly increased expression of the endogenous cyclin-dependent kinase inhibitor p21 CIP1 ( Figure 4a ). Furthermore, consistent with the known dependence of p21 CIP1 induction on the ERK Synergistic antileukemic interactions of MEK1/2 and HDAC inhibitors C Yu et al pathway, 33 coadministration of PD184352 dramatically diminished p21 CIP1 induction by SAHA. In addition, while SAHA modestly reduced expression of cyclin D 1 , coadministration of PD184352, which was ineffective by itself, markedly reduced expression of this protein.
SAHA slightly increased expression of phospho-p38 MAPK, while co-treatment with PD184352 had little further effect (Figure 4b ). On the other hand, while PD184352 or SAHA induced minimal activation of the stress-related kinase JNK, combined treatment resulted in a very pronounced increase in JNK phosphorylation.
Combined (but not individual) treatment of cells with PD184352 and SAHA also resulted in a clear reduction in levels of Raf-1. As anticipated, PD184352 essentially abrogated ERK phosphorylation, whereas SAHA reduced expression only slightly (Figure 4c ). Combined exposure to PD184352 and SAHA also resulted in abrogation of ERK activation, whereas total ERK levels remained unchanged with any treatment. In contrast, combined treatment with PD/SAHA significantly downregulated expression of MEK1 whereas individual treatment had little or no effect. In addition, individual exposure of cells to SAHA or PD184352 had little effect on the expression Synergistic antileukemic interactions of MEK1/2 and HDAC inhibitors C Yu et al (Figure 1c ), it remained possible that at least some of the perturbations noted above might represent secondary, caspasedependent events. To address this issue, cells were cotreated with PD184352 and SAHA for 24 h in the presence of the pancaspase inhibitor Boc-D-fmk (20 mM), after which expression of various cell cycle and signaling proteins was monitored. As shown in Figure 5a , cotreatment with Boc-D-fmk largely blocked PD184352/SAHA-mediated apoptosis. However, caspase inhibition had no effect on release of cytochrome c or AIF in the cytosolic S-100 fraction (Figure 5b ). In contrast, Smac/ DIABlO release was largely prevented by Boc-D-fmk, indicating that the latter event was caspase-dependent. Boc-D-fmk also blocked PD184352/SAHA-mediated caspase-3 cleavage as well as Bid downregulation, consistent with caspase-mediated degradation.
Parallel studies were performed to assess the caspasedependence of cell cycle and signaling perturbations in PD184352/SAHA-treated cells. Coadministration of Boc-D-fmk resulted in a modest although discernible increase in p21 CIP1 expression (Figure 5c ), suggesting that downregulation of this protein in SAHA/PD184352-treated cells was at least partly caspase-dependent. On the other hand, Boc-D-fmk was largely ineffective in reversing the downregulation of Raf-1 and phospho-ERK, indicating that these represent caspase-independent events. Finally, addition of Boc-D-fmk diminished the extent of Akt inactivation and downregulation of Bcr/Abl in treated cells, consistent with a caspase-dependent component to these phenomena (Figures 5d). HDACI-induced lethality has been associated with induction of ROS; 16 furthermore, the MEK/ERK pathway has been implicated in protecting cells from oxidative injury. 24 Therefore, the possibility arose that the lethal effects of the SAHA/ PD184352 regimen might stem from enhanced oxidative stress. To test this possibility, cells were exposed to these agents in the presence or absence of the free radical scavenger N-acetyl-Lcysteine (NAC). As shown in Figure 6a , PD184352 and SAHA (3 h) individually had little or no effect on ROS generation in K562 cells. However, combined treatment resulted in a marked increase in oxidative injury. The increase in ROS generation could be detected as early 0.5-1.0 h after drug exposure, and reached near maximal levels by 3-4 h (data not shown). Furthermore, coadministration of NAC significantly although incompletely attenuated the increase in ROS generation in SAHA/PD184352-treated cells (Po0.02). Notably, NAC significantly diminished the extent of apoptosis in cells exposed to these agents in combination (Po0.5 vs cells incubated with drugs in the absence of NAC; Figure 6b ), arguing that oxidative injury plays a functional role in the enhanced lethality of the SAHA/PD184352 regimen. Interestingly, addition of NAC failed to attenuate p21 CIP1 downregulation and JNK activation in SAHA/PD184352-treated cells (Figure 6c ), suggesting that these events occur, at least in part, upstream or independently of oxidative injury. Finally, Boc-D-fmk failed to block SAHA/ PD184352-mediated ROS generation (data not shown), indicating that induction of oxidative injury by this regimen represents a primary event. Equivalent results were observed when LAMA84 cells were treated with PD184352/SAHA in the presence or absence of NAC (data not shown). To test the functional significance of JNK activation in the lethality of this regimen, both genetic and pharmacologic approaches were employed. As shown in Supplementary Figure  S2 on website, inset, transfection of JNK1 siRNA substantially reduced expression of JNK1 in K562 cells, but had little effect on JNK2 levels. Analysis of cell death revealed that siRNAmediated knockdown of JNK1 failed to protect K562 cells from SAHA/PD184352-mediated lethality (Po0.05 vs controls). Identical results were obtained when the pharmacologic JNK inhibitor SP600125 was employed. Coadministration of SP600125 also failed to block the downregulation of p21 CIP1 and inactivation of ERK in SAHA/PD184352-treated cells, despite clearly diminishing JNK activation (Supplementary Figure S2 on website) . Together, these findings argue that JNK activation represents a consequence, rather than a cause, of SAHA/PD184352-mediated lethality and accompanying events.
Parallel studies were performed to assess the functional significance of p21 CIP1 downregulation and Akt inactivation in the lethality of this combination. Transient transfection of K562 cells with a p21 CIP1 construct resulted in an increase in p21 CIP1 expression in SAHA/PD184352-treated cells (Figure 7a, inset) , and partially but significantly protected them from SAHA/ PD184352-mediated lethality compared to GFP controls (Po0.05; Figure 7a ). The ability of ectopic expression of p21 CIP1 to prevent SAHA/PD184352-mediated p21 CIP1 downregulation is shown by the Western blot in Figure 7b . Attempts were also made to assess the functional significance of downregulation of the cytoprotective Akt pathway in SAHA/ PD184352-mediated lethality. To this end, K562 cells were transiently transfected with a constitutively active (myristolated) Akt construct and effects on various signaling events and cell death were then monitored. As shown by Western blot analysis in Figure 7c Lastly, an attempt was made to assess the functional contribution of inactivation/downregulation of MEK1 and Raf-1 in the enhanced lethality of this drug combination in leukemia cells. To this end, K562 cells were transiently transfected with constitutively active MEK1, after which cells were exposed for 24 h to SAHA and PD184352 as described above. As shown (Figure 8a The free radical scavenger NAC attenuates PD184352/ SAHA-mediated ROS generation and lethality but not p21 CIP1 downregulation or JNK activation. (a) K562 cells were either left untreated or pretreated with 15 mM NAC for 3 h followed by the addition of 10 mM PD18435272.0 mM of SAHA for 2 h. At the end of the drug exposure, ROS generation was monitored by flow cytometry using DHCF as dye as described in Materials and methods. (b) K562 cells were treated as in (a) for 48 h, after which cell viability was monitored by 7-AAD uptake as described previously. Values represent the mean7s.d. for three separate experiments performed in triplicate.
n Significantly less than values for PD184352 þ SAHA in the absence of NAC; Po0.02. (c) K562 cells were treated as above for 16 h after which they were lysed and subjected to Western blot analysis using the indicated primary antibodies. Lanes were loaded with 20 mg of protein; blots were stripped and reprobed with antitubulin antibodies to ensure equal loading and transfer of proteins. Two additional experiments yielded equivalent results.
Synergistic antileukemic interactions of MEK1/2 and HDAC inhibitors C Yu et al lethality in K562 cells, whereas diminished expression of Raf-1 represents a secondary phenomenon.
Discussion
The results of the present study indicate that interruption of the MEK/ERK pathway lowers the threshold for HDACI-mediated apoptosis in Bcr/Abl þ leukemia cells, including some resistant to more specifically targeted agents (eg imatinib mesylate). The Bcr/Abl kinase activates multiple downstream cytoprotective signaling cascades, including those related to PI3K/Akt, Stat, NF-kB, and ERK, among others. [2] [3] [4] 6 In this regard, ERK activation has been specifically linked to the prosurvival activities of Bcr/Abl in CML cells. 21 Moreover, the net balance between proapoptotic signaling pathways such as ERK and stress-related cascades (eg JNK) is known to be a critical determinant of cell fate. 23 While the proapoptotic actions of HDACIs are pleiotropic, 16 downregulation of prosurvival signaling pathways may play an important role in the lethality of this class of agents. Such effects may stem from HDACImediated perturbations in gene expression, or, alternatively, in alterations in the function of chaperone proteins (eg Hsp90) resulting in misfolding and subsequent degradation of various members of survival signaling cascades. 17 Recently, it has been shown that reciprocal effects on the MEK/ERK and JNK pathways represent critical determinants of HDACI-mediated lethality in Bcr/Abl þ leukemia cells. 21 Thus, it seemed reasonable to postulate that disabling the cytoprotective MEK/ERK cascade by pharmacologic means would shift the balance away from Enforced expression of constitutively active MEK1 protects cells from SAHA/PD184352-mediated lethality. K562 cells were transiently transfected with a (a) pUSE-MEK1-CA construct, or with a pUSE empty vector control and maintained for 24 h after which they were exposed to PD184352 (10 mM) and SAHA (2.0 mM) for an additional 36 h. Viability was then determined by 7-AAD uptake as described earlier. (b) Cells were transiently transfected with respective constructs as above. After 24 h of incubation, cells were exposed to PD184352 (10 mM) and SAHA (2.0 mM) for an additional 12 h, after which cells were lysed and Western blot analysis employed to monitor expression of the indicated proteins. Each lane was loaded with 20 mg of protein; blots were stripped and reprobed with antitubulin antibodies to ensure equal loading and transfer of proteins. An additional study yielded equivalent results. CIP1 construct or a GFP empty vector and maintained for 24 h after which they were exposed to PD184352 (10 mM) and SAHA (2.0 mM) is for an additional 36 h. Viability was then determined by 7-AAD uptake as described above. Inset: Western blot analysis of expression of p21 CIP1 in cells transiently transfected with GFP and p21 CIP1 constructs. (b) K562 cells were transfected with a pUSB empty vector or the GFP-p21 CIP1 construct treated as above, for 12 h after which Western blot analysis was employed to monitor p21 CIP1 expression. (c) Cells were transiently transfected with Akt-CA constructs or empty vector controls, for example, pSUB. After 24 h incubation, PD184352 (10 mM) and SAHA (2.0 mM) were added for another 12 h, after which cells were lysed and Western blot analysis employed to monitor expression of the indicated proteins. (d) Cells were transiently transfected with CA-Akt or empty vector constructs as described above in (c) for 24 h, after which they were exposed to PD184352 (10 mM) and SAHA (2.0 mM) for 36 h. 21 The mechanism by which this phenomenon occurs is not known with certainty, but may involve alterations in the expression of redox-related genes (eg thioredoxin, superoxide dismutase). 35 Moreover, activation of the MEK/ERK cascade is a well-described response to oxidative injury. 24 Thus, by disabling the MEK/ERK pathway, MEK inhibitors such as PD184352 may render cells more sensitive to the lethal actions of HDACIs, which act in part by triggering oxidative injury. In support of this notion, ROS generation was strikingly increased in cells simultaneously exposed to SAHA and PD184352. These findings are consistent with earlier results indicating that the lethal effects of high concentrations of HDACIs administered alone are associated with ROS generation. 16 In each case, coadministration of the free radical scavenger NAC significantly attenuated lethality, suggesting a causal role for oxidative damage in the induction of apoptosis. It should be noted that in cells exposed to MEK and HDAC inhibitors, protection by NAC was not complete, suggesting that additional factors are likely to be involved in the lethal effects of this regimen. Nevertheless, the present results argue strongly that enhanced oxidative injury plays an important functional role in synergistic interactions between PD184352 and HDACIs in Bcr/Abl þ leukemia cells. In this context, it is note worthy that recent studies suggest that HDACI selectively induce oxidative damage in neoplastic cells, 36 which may explain the preferential lethality of the MEK/HDAC inhibitors regimen towards CML vs normal cells.
Activation of the stress-related JNK pathway has long been known to play a key role in oxidative injury-associated cell death, and has been associated with induction of apoptosis in Bcr/Abl þ leukemic cells by high concentrations of HDAC inhibitors. 21 It was therefore logical to assume that activation of the JNK pathway played a key role in synergistic interactions between SAHA and MEK1/2 inhibitors, However, contrary to expectations, inhibition of this cascade by either pharmacologic (eg SP600125) or genetic (eg JNK1 siRNA) means failed to attenuate SAHA/PD184352-mediated lethality. Such findings, along with the partial caspase-dependence of phospho-JNK upregulation, argue that in this setting, JNK activation represents a consequence, rather than a cause, of oxidative damageinduced lethality.
Based upon the present findings, it is reasonable to conclude that downregulation of p21 CIP1 in SAHA/PD184352-treated cells contributes to synergistic interactions between these agents. p21 CIP1 can oppose apoptosis through multiple mechanisms including inactivation of caspase-3 and/or JNK. In addition, endogenous CDK inhibitors (eg p16 INK4 ) are known to block HDAC inhibitor-induced cell cycle perturbations and lethality. In this context, dysregulation of p21 CIP1 by either antisense strategies or pharmacologic inhibitors such as flavopiridol have been shown to increase the lethality of HDAC inhibitors in human leukemia cells. 32 The regulation of p21 CIP1 expression is complex and may occur at multiple levels. For example, the caspase-mediated cleavage of p21 CIP1 in cells undergoing apoptosis is well described. 15 Furthermore, given evidence that p21 CIP1 induction is MEK/ERK-dependent, it is likely that ERK inactivation by PD184352 contributed, at least in part, to reduced expression of this CDKI. In addition, Akt has been shown to stabilize p21 CIP1 , 37, 38 consistent with the observation that enforced expression of constitutively active Akt attenuated SAHA/PD184352-mediated p21 CIP1 downregulation. Thus, although downregulation of p21 CIP1 in SAHA/PD184352-treated cells was at least partly caspase-dependent, the notion that reduced expression of this CDKI contributes to the increase in HDAC inhibitor-mediataed lethality appears plausible. This conclusion is reinforced by the finding that enforced expression of p21 CIP1 significantly protected cells from the lethality of this regimen.
Synergistic interactions between SAHA and PD184352 in Bcr/ Abl þ cells were associated with downregulation/inactivation of the cytoprotective Akt pathway. Furthermore, the ability of enforced activation of Akt to protect cells from this drug combination supports the notion that disruption of Akt signaling plays a functional role in the observed lethality. It should be noted that diminished expression of total and phosphorylated Akt was attenuated by caspase inhibition, consistent with evidence that signaling proteins in general, 39, 40 and Akt in particular, 41 are subject to caspase-dependent degradation. Alternatively, inactivation of Akt, as well as other signaling proteins (eg Bcr/Abl, Raf/MEK/ERK) may reflect acetylation of chaperones such as Hsp90, leading to misfolding and degradation of client proteins. Whatever the mechanism, Akt, like ERK, has also been shown to play a role in protecting cells from the lethal consequences of oxidative stress. 42 In addition, cross-talk between the ERK and Akt cascades has been described, 43 and combined downregulation of both Akt and ERK may be considerably more lethal than interruption of either pathway alone. Significantly, both the Raf/MEK/ERK and Akt pathways have been implicated in conferring a survival advantage to cells expressing the Bcr/Abl kinase. 44 It is noteworthy that ectopic expression of both constitutively active Akt and MEK1 constructs significantly protected cells from SAHA/PD184352 lethality, suggesting a functional role for interruption of these pathways in antileukemic synergism. In contrast, attenuation of Raf-1 downregulation did not protect cells, arguing against a major role for this event in enhanced lethality. Finally, the downregulation of Bcr/Abl in SAHA/PD184352-treated cells, although at least partially caspase-dependent, may nevertheless have contributed to inactivation of downstream survival cascades. Consequently, inactivation of multiple signaling pathways by SAHA/PD184352, whether by direct or indirect means, may substantially lower the threshold of Bcr/Abl þ cells to oxidative injury, mitochondrial dysfunction and cell death.
In summary, the present studies provide several novel findings including the observations that (1) combined HDAC and MEK1 inhibition using clinically relevant agents synergistically promotes apoptosis in Bcr/Abl þ leukemia cells; (2) this phenomenon involves induction of oxidative damage and ROS generation; (3) enhanced lethality occurs in at least some primary Bcr/Abl þ leukemia cells and in some K562 cells resistant to imatinib mesylate; (4) this regimen is relative nontoxic to normal CD34 þ bone marrow cells; (5) combined exposure to MEK and HDACIs leads to downregulation/ inactivation of p21 CIP1 , Akt, and MEK1/ERK, all of which play significant functional roles in enhanced lethality; (6) in contrast, downregulation of Raf-1 and activation of JNK in SAHA/ PD184352-treated cells appear to represent secondary phenomena; and (7) MEK/HDAC inhibition results in the partially caspase-dependent downregulation of Bcr/Abl, which may also contribute to lethality. While Bcr/Abl kinase inhibitors such as imatinib mesylate have had a major impact on the treatment of CML and related diseases, the emergence of drug resistance remains a major problem. 9 In this regard, it is particularly noteworthy that the MEK/HDAC inhibitor regimen was active against some primary and imatinib mesylate-resistant CML cells, and relatively nontoxic to normal progenitors. However, the small number of CML specimens evaluated preclude making generalizations concerning the activity of this regimen in primary specimens, and clearly a larger size will be required to resolve this issue. In any case, recent studies indicate that mutations in the Bcr/Abl kinase domain can render CML cells highly resistant to imatinib mesylate in vitro, 45 and several of these mutations have been detected in cells obtained from patients refractory to this agent. 46 Although the development of second-generation Bcr/Abl kinase inhibitors such as BMS-354825 and AMN107, which retain activity against cells bearing most kinase mutations, 10 represents a basis for optimism, certain mutations (eg T315I) remain refractory to these agents (Talpaz et al. Blood 2004; 104: 10a; abstract #20). In addition, as such agents enter the therapeutic armamentarium, it is conceivable that new Bcr/Abl mutations will appear conferring resistance to such second-generation kinase inhibitors. On the other hand, there is no a priori reason why cells exhibting Bcr/Abl kinase mutations should be resistant to regimens acting through induction of oxidative damage and interruption of survival signaling pathways downstream of Bcr/ Abl. Such regimens might prove useful either alone or as adjuncts designed to delay or prevent the emergence of leukemic cells resistant to Bcr/Abl kinase inhibitors. The ultimate efficacy of this approach will depend upon whether this strategy will be sufficiently selective and active in the in vivo setting. Accordingly, efforts to address these questions are currently underway.
